Company intelligence / Profile preview

Sling Therapeutics, Inc.

Ann Arbor, Michigan, United Statesslingtx.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Positive topline results from Phase 2b/3 LIDS clinical trial of linsitinib announced in January 2025. The trial met its primary endpoint of proptosis reduction with statistical significance at 150mg BID dose. Linsitinib was well-tolerated with no drug-related hearing impairments or significant hyperglycemia. A confirmatory Phase 3 trial is on track to commence in 2025.

Therapeutic areas: EndocrinologyRare Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

linsitinib

Beyond the preview

Go deeper on Sling Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sling Therapeutics, Inc..

Explore the full profile